Research Analysts Issue Forecasts for FDMT FY2025 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Analysts at Cantor Fitzgerald lowered their FY2025 EPS estimates for shares of 4D Molecular Therapeutics in a research report issued to clients and investors on Tuesday, November 11th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings of ($3.70) per share for the year, down from their prior estimate of ($3.60). The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share. Cantor Fitzgerald also issued estimates for 4D Molecular Therapeutics’ FY2026 earnings at ($2.60) EPS.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Monday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%.The business had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.40 million.

Other equities research analysts also recently issued reports about the stock. Chardan Capital upped their price objective on shares of 4D Molecular Therapeutics from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday. Barclays cut their price objective on shares of 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday. Roth Capital lowered their target price on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a report on Tuesday, August 12th. Morgan Stanley raised 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a report on Friday, November 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, October 8th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.70.

4D Molecular Therapeutics Stock Performance

Shares of FDMT opened at $10.28 on Thursday. 4D Molecular Therapeutics has a fifty-two week low of $2.23 and a fifty-two week high of $12.34. The business has a 50-day moving average of $9.25 and a 200 day moving average of $6.21. The firm has a market cap of $587.30 million, a P/E ratio of -2.74 and a beta of 2.96.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC boosted its position in shares of 4D Molecular Therapeutics by 117.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after acquiring an additional 2,674 shares during the last quarter. Abich Financial Wealth Management LLC purchased a new stake in 4D Molecular Therapeutics in the third quarter valued at approximately $80,000. Inscription Capital LLC bought a new stake in 4D Molecular Therapeutics during the third quarter valued at approximately $94,000. Impact Partnership Wealth LLC purchased a new position in 4D Molecular Therapeutics in the 3rd quarter worth approximately $96,000. Finally, Quadrature Capital Ltd purchased a new position in 4D Molecular Therapeutics in the 2nd quarter worth approximately $42,000. 99.27% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock in a transaction on Friday, October 24th. The stock was sold at an average price of $12.00, for a total transaction of $32,136.00. Following the completion of the sale, the insider owned 3,594 shares of the company’s stock, valued at approximately $43,128. This trade represents a 42.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 9,128 shares of company stock valued at $92,100 in the last quarter. Company insiders own 9.60% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.